These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32278335)

  • 1. Combination of cyclic nucleotide modulators with P2Y
    Armstrong PC; Ferreira PM; Chan MV; Lundberg Slingsby MH; Crescente M; Shih CC; Kirkby NS; Hobbs AJ; Warner TD
    J Thromb Haemost; 2020 Jul; 18(7):1705-1713. PubMed ID: 32278335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet inhibition by P2Y
    Shih CC; Chan MV; Kirkby NS; Vojnovic I; Mitchell JA; Armstrong PC; Warner TD
    Br J Pharmacol; 2021 Dec; 178(23):4758-4771. PubMed ID: 34383973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation.
    Chan MV; Knowles RB; Lundberg MH; Tucker AT; Mohamed NA; Kirkby NS; Armstrong PC; Mitchell JA; Warner TD
    Br J Clin Pharmacol; 2016 Apr; 81(4):621-33. PubMed ID: 26561399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y
    Brambilla M; Becchetti A; Rovati GE; Cosentino N; Conti M; Canzano P; Giesen PLA; Loffreda A; Bonomi A; Cattaneo M; De Candia E; Podda GM; Trabattoni D; Werba PJ; Campodonico J; Pinna C; Marenzi G; Tremoli E; Camera M
    Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):2042-2057. PubMed ID: 37589138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
    Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
    Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
    Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
    Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
    Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
    Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
    J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of platelet P2Y
    Parker WAE; Storey RF
    Br J Pharmacol; 2024 Feb; 181(4):515-531. PubMed ID: 37771103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
    Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
    Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y
    Li X; Liu P; Xu Z; Sun D; Gu J; Miao Y; Zhang J; Cao X
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):15-23. PubMed ID: 32062793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Function and Regulation of Platelet P2Y12 Receptor.
    Li X; Zhang G; Cao X
    Cardiovasc Drugs Ther; 2023 Feb; 37(1):199-216. PubMed ID: 34319489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats.
    Sugidachi A; Yamaguchi S; Jakubowski JA; Ohno K; Tomizawa A; Hashimoto M; Niitsu Y
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):329-34. PubMed ID: 21697729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y
    Panzer B; Wadowski PP; Huber K; Panzer S; Gremmel T
    Diabet Med; 2022 Aug; 39(8):e14868. PubMed ID: 35514270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
    Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
    J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y
    Wolska N; Boncler M; Polak D; Wzorek J; Przygodzki T; Gapinska M; Watala C; Rozalski M
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31905703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of fentanyl with blood platelets and plasma proteins: platelet sensitivity to prasugrel metabolite is not affected by fentanyl under in vitro conditions.
    Bednarek R; Luzak B; Golański J; Boncler M
    Pharmacol Rep; 2023 Apr; 75(2):423-441. PubMed ID: 36646965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.